Insuli

SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference

- Canadian Biotechnology Company updates progress and upcomingmilestones on its insulin program - CALGARY, June 26, 2007 /PRNewswire-FirstCall/ - SemBioSysGenetics Inc. , a biotechnology company developing a portfolio oftherapeutic proteins for metabolic and cardiovascular disease,today announced positive preclinical data supporting thedevelopment of plant-derived recombinant human insuli...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen InInsulin Therapy CHICAGO, June 24, 2007 – Novo Nordisk today announcedresults of a new study that further demonstrated the safety andefficacy of insulin Levemir® (insulin detemir [rDNA origin]injection). Patients with Type 2 diabetes were able to adjusttheir own dosage of Levemir® and achieve improvements i...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen InInsulin Therapy CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Novo Nordisktoday announced results of a new study that further demonstratedthe safety and efficacy of insulin Levemir(R) (insulin detemir[rDNA origin] injection). Patients with type 2 diabetes were ableto adjust their own dosage of Levemir(R) and achieve improvem...

Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting

EXETER, N.H.--(BUSINESS WIRE)--Jun 25, 2007 - BentleyPharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceuticalcompany, today announced positive clinical results in threeCompany-sponsored studies of its investigational drug, Nasulin(TM),an intranasal insulin spray. The data were presented this pastweekend at the American Diabetes Association 67th ScientificSessions in Chicago. In a pl...

Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study

COPENHAGEN, June 21, 2007-Novo Nordisk today announced clinicalresults from the first of five phase 3 studies with liraglutide -the once-daily human GLP-1 analogue. The 26-week study is part ofthe LEAD(TM) (Liraglutide Effect and Action in Diabetes) programmeand included 581 patients with type 2 diabetes inadequatelycontrolled by two of the most widely used oral antidiabetic drugs:metfor...

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM)Therapeutics, Inc. , a biopharmaceutical company focused on thetreatment of central nervous system disorders with an initial focuson obesity, today announced that the Company will present dataabout its lead obesity product candidate Contrave(TM) and itseffect on markers of cardiovascular disease (visceral fat, serumcholestero...

Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter

MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today that the Companyintends to initiate a Phase 1b clinical trial to demonstrate theefficacy and safety of the improved formulation of its transdermalinsulin product, TPM-02/Insulin, containing long-acting insulin.The trial is expected to commence in the second quarter of2007....

Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference

Findings Suggest Insulin Powder Produced Using Baxter's PROMAXXMicrosphere Technology was Absorbed Systemically with No ReportedCough or Shortness of Breath PARIS, April 20, 2007 /PRNewswire-FirstCall/ -- BaxterHealthcare Corporation announced results of a Phase I study thatevaluated pulmonary insulin produced with Baxter's PROMAXXmicrosphere technology and administered using a small, sta...

GTx Announces Ostarine Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial

MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr 17, 2007 - GTx, Inc. (NASDAQ:GTXI) announced today that data from a recently conducted Phase IIOstarine(TM) clinical trial of 60 elderly men and 60 postmenopausalwomen revealed that insulin and glucose levels were reduced andinsulin resistance was improved among subjects receiving the 3 mgdose of Ostarine compared to baseline. These observations were even...